Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 3Phase 1/2 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Famotidine × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡